Reverse genetics approaches for the development of influenza vaccines

International Journal of Molecular Sciences

Volumn 18, Issue 1, 2017, Pages

  Nogales, Aitor ^a   Martínez Sobrido, Luis ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Antivirals; Influenza inactivated virus; Influenza vaccines; Influenza virus; Live attenuated influenza virus; Recombinant influenza virus; Reverse genetics; Universal vaccines; Vaccination

Indexed keywords

ADJUVANT; AMANTADINE; HEMAGGLUTININ; INFLUENZA VACCINE; INTERFERON; MIFAMURTIDE; MUSCARINIC M2 RECEPTOR ANTAGONIST; NEUTRALIZING ANTIBODY; OSELTAMIVIR; RIBONUCLEOPROTEIN; RIMANTADINE; SIALIDASE; ZANAMIVIR; LIVE VACCINE; RECOMBINANT VACCINE;

ARTICLE; CELLULAR IMMUNITY; GENE MUTATION; GENETIC CODE; GENOME ANALYSIS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLUENZA; INFLUENZA A VIRUS; INFLUENZA B VIRUS; LIFE CYCLE ASSESSMENT; NONHUMAN; REVERSE GENETICS; VIRUS GENOME; VIRUS RESISTANCE; ANIMAL; GENETICS; IMMUNOLOGY; PROCEDURES;

ANIMALS; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; REVERSE GENETICS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 85007359609     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18010020     Document Type: Article

References (206)

1. Palese, P.S.; Shaw, M.L. Orthomyxoviridae: The viruses and their replication. In Fields Virology, 5th ed.; Knipe, D.M., Howley, P.M., Griffin, D.E., Lamb, R.A., Martin, M.A., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2007.
2. Steel, J.; Lowen, A.C.; Mubareka, S.; Palese, P. Transmission of influenza virus in a mammalian host is increased by PB2 amino acids 627K or 627E/701N. PLoS Pathog. 2009, 5, e1000252. [CrossRef] [PubMed]
3. Parrish, C.R.; Kawaoka, Y. The origins of new pandemic viruses: The acquisition of new host ranges by canine parvovirus and influenza A viruses. Annu. Rev. Microbiol. 2005, 59, 553-586. [CrossRef] [PubMed]
4. Bean, W.J.; Schell, M.; Katz, J.; Kawaoka, Y.; Naeve, C.; Gorman, O.; Webster, R.G. Evolution of the H3 influenza virus hemagglutinin from human and nonhuman hosts. J. Virol. 1992, 66, 1129-1138. [PubMed]
5. Chen, R.; Holmes, E.C. The evolutionary dynamics of human influenza B virus. J. Mol. Evol. 2008, 66, 655-663. [CrossRef] [PubMed]
6. Osterhaus, A.D.; Rimmelzwaan, G.F.; Martina, B.E.; Bestebroer, T.M.; Fouchier, R.A. Influenza B virus in seals. Science 2000, 288, 1051-1053. [CrossRef] [PubMed]
7. Resa-Infante, P.; Jorba, N.; Coloma, R.; Ortin, J. The influenza virus rna synthesis machine: Advances in its structure and function. RNA Biol. 2011, 8, 207-215. [CrossRef] [PubMed]
8. Neumann, G.; Brownlee, G.G.; Fodor, E.; Kawaoka, Y. Orthomyxovirus replication, transcription, and polyadenylation. Curr. Top. Microbiol. Immunol. 2004, 283, 121-143. [PubMed]
9. Huang, T.S.; Palese, P.; Krystal, M. Determination 0of influenza virus proteins required for genome replication. J. Virol. 1990, 64, 5669-5673. [PubMed]
10. Wright, P.; Nuemann, G.; Kawaoka, Y. Orthomhxoviruses. In Fields Virology, 5th ed.; Knipe, D.M., Howley, P.M., Griffin, D.E., Lamb, R.A., Martin, M.A., Eds.; LippincottWilliams & Wilkins: Philadelphia, PA, USA, 2007.
11. Stoeckle, M.Y.; Shaw, M.W.; Choppin, P.W. Segment-specific and common nucleotide sequences in the noncoding regions of influenza B virus genome RNAs. Proc. Natl. Acad. Sci. USA 1987, 84, 2703-2707. [CrossRef] [PubMed]
12. Baker, S.F.; Nogales, A.; Finch, C.; Tuffy, K.M.; Domm,W.; Perez, D.R.; Topham, D.J.; Martinez-Sobrido, L. Influenza A and B virus intertypic reassortment through compatible viral packaging signals. J. Virol. 2014, 88, 10778-10791. [CrossRef] [PubMed]
13. Jackson, D.; Elderfield, R.A.; Barclay, W.S. Molecular studies of influenza B virus in the reverse genetics era. J. Gen. Virol. 2011, 92, 1-17. [CrossRef] [PubMed]
14. Wise, H.M.; Hutchinson, E.C.; Jagger, B.W.; Stuart, A.D.; Kang, Z.H.; Robb, N.; Schwartzman, L.M.; Kash, J.C.; Fodor, E.; Firth, A.E.; et al. Identification of a novel splice variant form of the influenza A virus M2 ion channel with an antigenically distinct ectodomain. PLoS Pathog. 2012, 8, e1002998. [CrossRef] [PubMed]
15. Horvath, C.M.; Williams, M.A.; Lamb, R.A. Eukaryotic coupled tanslation of tandem cistrons: Identification of the influenza B virus BM2 polypeptide. EMBO J. 1990, 9, 2639-2647. [PubMed]
16. Skehel, J.J.; Wiley, D.C. Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu. Rev. Biochem. 2000, 69, 531-569. [CrossRef] [PubMed]
17. Varghese, J.N.; McKimm-Breschkin, J.L.; Caldwell, J.B.; Kortt, A.A.; Colman, P.M. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 1992, 14, 327-332. [CrossRef] [PubMed]
18. Tulip,W.R.; Varghese, J.N.; Laver,W.G.;Webster, R.G.; Colman, P.M. Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complex. J. Mol. Biol. 1992, 227, 122-148. [CrossRef]
19. Yoon, S.W.; Webby, R.J.; Webster, R.G. Evolution and ecology of influenza A viruses. Curr. Top. Microbiol. Immunol. 2014, 385, 359-375. [PubMed]
20. Tong, S.; Zhu, X.; Li, Y.; Shi, M.; Zhang, J.; Bourgeois, M.; Yang, H.; Chen, X.; Recuenco, S.; Gomez, J.; et al. New world bats harbor diverse influenza A viruses. PLoS Pathog. 2013, 9, e1003657. [CrossRef] [PubMed]
21. McCullers, J.A.; Saito, T.; Iverson, A.R. Multiple genotypes of influenza B virus circulated between 1979 and 2003. J. Virol. 2004, 78, 12817-12828. [CrossRef] [PubMed]
22. Kanegae, Y.; Sugita, S.; Endo, A.; Ishida, M.; Senya, S.; Osako, K.; Nerome, K.; Oya, A. Evolutionary pattern of the hemagglutinin gene of influenza B viruses isolated in japan: Cocirculating lineages in the same epidemic season. J. Virol. 1990, 64, 2860-2865. [PubMed]
23. Thompson, W.W.; Shay, D.K.; Weintraub, E.; Brammer, L.; Cox, N.; Anderson, L.J.; Fukuda, K. Mortality associated with influenza and respiratory syncytial virus in the united states. JAMA 2003, 289, 179-186. [CrossRef] [PubMed]
24. Li, W.C.; Shih, S.R.; Huang, Y.C.; Chen, G.W.; Chang, S.C.; Hsiao, M.J.; Tsao, K.C.; Lin, T.Y. Clinical and genetic characterization of severe influenza B-associated diseases during an outbreak in Taiwan. J. Clin. Virol. 2008, 42, 45-51. [CrossRef] [PubMed]
25. Hite, L.K.; Glezen, W.P.; Demmler, G.J.; Munoz, F.M. Medically attended pediatric influenza during the resurgence of the victoria lineage of influenza B virus. Int. J. Infect. Dis. 2007, 11, 40-47. [CrossRef] [PubMed]
26. Pinto, L.H.; Holsinger, L.J.; Lamb, R.A. Influenza virus M2 protein has ion channel activity. Cell 1992, 69, 517-528. [CrossRef]
27. Lamb, R.A.; Choppin, P.W. The gene structure and replication of influenza virus. Annu. Rev. Biochem. 1983, 52, 467-506. [CrossRef] [PubMed]
28. Hutchinson, E.C.; von Kirchbach, J.C.; Gog, J.R.; Digard, P. Genome packaging in influenza A virus. J. Gen. Virol. 2010, 91, 313-328. [CrossRef] [PubMed]
29. Rossman, J.S.; Lamb, R.A. Influenza virus assembly and budding. Virology 2011, 411, 229-236. [CrossRef] [PubMed]
30. Gerber, M.; Isel, C.; Moules, V.; Marquet, R. Selective packaging of the influenza A genome and consequences for genetic reassortment. Trends Microbiol. 2014, 22, 446-455. [CrossRef] [PubMed]
31. Hale, B.G.; Randall, R.E.; Ortin, J.; Jackson, D. The multifunctional NS1 protein of influenza A viruses. J. Gen. Virol. 2008, 89, 2359-2376. [CrossRef] [PubMed]
32. Paterson, D.; Fodor, E. Emerging roles for the influenza A virus nuclear export protein (NEP). PLoS Pathog. 2012, 8, e1003019. [CrossRef] [PubMed]
33. Ampofo, W.K.; Baylor, N.; Cobey, S.; Cox, N.J.; Daves, S.; Edwards, S.; Ferguson, N.; Grohmann, G.; Hay, A.; Katz, J.; et al. Improving influenza vaccine virus selection: Report of a WHO informal consultation held at WHO headquarters, geneva, switzerland, 14-16 June 2010. Influenza Other Respir. Viruses 2013, 7, 52-53. [PubMed]
34. Barr, I.G.; McCauley, J.; Cox, N.; Daniels, R.; Engelhardt, O.G.; Fukuda, K.; Grohmann, G.; Hay, A.; Kelso, A.; Klimov, A.; et al. Epidemiological, antigenic and genetic characteristics of seasonal influenza A (H1N1), a(H3N2) and B influenza viruses: Basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 northern hemisphere season. Vaccine 2010, 28, 1156-1167. [CrossRef] [PubMed]
35. Cox, N.J.; Brammer, T.L.; Regnery, H.L. Influenza: Global surveillance for epidemic and pandemic variants. Eur. J. Epidemiol. 1994, 10, 467-470. [CrossRef] [PubMed]
36. Kang, S.M.; Song, J.M.; Compans, R.W. Novel vaccines against influenza viruses. Virus Res. 2011, 162, 31-38. [CrossRef] [PubMed]
37. Lynch, J.P., 3rd; Walsh, E.E. Influenza: Evolving strategies in treatment and prevention. Semin. Respir. Crit. Care Med. 2007, 28, 144-158. [CrossRef] [PubMed]
38. Molinari, N.A.; Ortega-Sanchez, I.R.; Messonnier, M.L.; Thompson, W.W.; Wortley, P.M.; Weintraub, E.; Bridges, C.B. The annual impact of seasonal influenza in the us: Measuring disease burden and costs. Vaccine 2007, 25, 5086-5096. [CrossRef] [PubMed]
39. Girard, M.P.; Cherian, T.; Pervikov, Y.; Kieny, M.P. A review of vaccine research and development: Human acute respiratory infections. Vaccine 2005, 23, 5708-5724. [CrossRef] [PubMed]
40. Keech, M.; Beardsworth, P. The impact of influenza on working days lost: A review of the literature. Pharmacoeconomics 2008, 26, 911-924. [CrossRef] [PubMed]
41. Paul Glezen,W.; Schmier, J.K.; Kuehn, C.M.; Ryan, K.J.; Oxford, J. The burden of influenza B: A structured literature review. Am. J. Public Health 2013, 103, e43-e51. [CrossRef] [PubMed]
42. Gasparini, R.; Amicizia, D.; Lai, P.L.; Panatto, D. Clinical and socioeconomic impact of seasonal and pandemic influenza in adults and the elderly. Hum. Vaccines Immunother. 2012, 8, 21-28. [CrossRef] [PubMed]
43. Smith, G.J.; Vijaykrishna, D.; Bahl, J.; Lycett, S.J.; Worobey, M.; Pybus, O.G.; Ma, S.K.; Cheung, C.L.; Raghwani, J.; Bhatt, S.; et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009, 459, 1122-1125. [CrossRef] [PubMed]
44. Kilbourne, E.D. Influenza pandemics of the 20th century. Emerg. Infect. Dis. 2006, 12, 9-14. [CrossRef] [PubMed]
45. Carrat, F.; Flahault, A. Influenza vaccine: The challenge of antigenic drift. Vaccine 2007, 25, 6852-6862. [CrossRef] [PubMed]
46. Xu, X.; Lindstrom, S.E.; Shaw, M.W.; Smith, C.B.; Hall, H.E.; Mungall, B.A.; Subbarao, K.; Cox, N.J.; Klimov, A. Reassortment and evolution of current human influenza A and B viruses. Virus Res. 2004, 103, 55-60. [CrossRef] [PubMed]
47. Sandbulte, M.R.; Westgeest, K.B.; Gao, J.; Xu, X.; Klimov, A.I.; Russell, C.A.; Burke, D.F.; Smith, D.J.; Fouchier, R.A.; Eichelberger, M.C. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc. Natl. Acad. Sci. USA 2011, 108, 20748-20753. [CrossRef] [PubMed]
48. Shaw, M.L.; Palese, P. Orthomyxoviridae. In Fields Virology, 6th ed.; Knipe, D.M., Howley, P.M., Eds.; LippincottWilliams & Wilkins: Philadelphia, PA, USA, 2013.
49. Mikheeva, A.; Ghendon, Y.Z. Intrinsic interference between influenza A and B viruses. Arch. Virol. 1982, 73, 287-294. [CrossRef] [PubMed]
50. Knipe, D.M.; Howley, P.M. Fields Virology, 6th ed.;Wolters Kluwer/LippincottWilliams &Wilkins Health: Philadelphia, PA, USA, 2013; p. 2.
51. Taubenberger, J.K.; Morens, D.M. 1918 influenza: The mother of all pandemics. Emerg. Infect. Dis. 2006, 12, 15-22. [CrossRef] [PubMed]
52. CDC. Update: Infections with a swine-Origin influenza A (H1N1) virus-United States and other countries, April 28, 2009. MMWR Morb. Mortal. Wkly. Rep. 2009, 58, 431-433.
53. WHO. Pandemic (H1N1) 2009-Update 112. Available online: http://www.who.int/csr/don/2010_08_06/ en/index.html (accessed on 20 December 2016).
54. Uyeki, T.M.; Cox, N.J. Global concerns regarding novel influenza A (H7N9) virus infections. N. Engl. J. Med. 2013, 368, 1862-1864. [CrossRef] [PubMed]
55. Yen, H.L.; Webster, R.G. Pandemic influenza as a current threat. Curr. Top. Microbiol. Immunol. 2009, 333, 3-24. [PubMed]
56. Brotherton, J.M.; Delpech, V.C.; Gilbert, G.L.; Hatzi, S.; Paraskevopoulos, P.D.; McAnulty, J.M. A large outbreak of influenza A and B on a cruise ship causing widespread morbidity. Epidemiol. Infect. 2003, 130, 263-271. [CrossRef] [PubMed]
57. CDC. From the centers for disease control and prevention. Influenza B virus outbreak in a cruise ship-Northern europe, 2000. JAMA 2001, 285, 1833-1834.
58. DeStefano, F. An outbreak of influenza B at an indiana boarding school: Estimate of vaccine efficacy. Public Health Rep. 1982, 97, 269-272. [PubMed]
59. Fayinka, O.A.; Balayan, M.S.; Kirya, G.B.; Rugyendo, W. An outbreak of influenza B in a closed community school in Uganda. East. Afr. Med. J. 1977, 54, 6-8. [PubMed]
60. Gordon Smith, C.E.; Thomson, W.G. An outbreak of influenza due to type B virus in a residential boys’ school in Malaya. Med. J. Malaya 1956, 10, 332-337. [PubMed]
61. Osterholm, M.T.; Kelley, N.S.; Sommer, A.; Belongia, E.A. Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. Lancet Infect. Dis. 2012, 12, 36-44. [CrossRef]
62. De Jong, M.D.; Tran, T.T.; Truong, H.K.; Vo, M.H.; Smith, G.J.; Nguyen, V.C.; Bach, V.C.; Phan, T.Q.; Do, Q.H.; Guan, Y.; et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 2005, 353, 2667-2672. [CrossRef] [PubMed]
63. Hurt, A.C.; Holien, J.K.; Parker, M.; Kelso, A.; Barr, I.G. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol. 2009, 83, 10366-10373. [CrossRef] [PubMed]
64. Monto, A.S.; McKimm-Breschkin, J.L.; Macken, C.; Hampson, A.W.; Hay, A.; Klimov, A.; Tashiro, M.; Webster, R.G.; Aymard, M.; Hayden, F.G.; et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob. Agents Chemother. 2006, 50, 2395-2402. [CrossRef] [PubMed]
65. Belshe, R.B.; Edwards, K.M.; Vesikari, T.; Black, S.V.;Walker, R.E.; Hultquist, M.; Kemble, G.; Connor, E.M. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 2007, 356, 685-696. [CrossRef] [PubMed]
66. Belshe, R.B.; Newman, F.K.; Wilkins, K.; Graham, I.L.; Babusis, E.; Ewell, M.; Frey, S.E. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 2007, 25, 6755-6763. [CrossRef] [PubMed]
67. Pronker, E.S.; Claassen, E.; Osterhaus, A.D. Development of new generation influenza vaccines: Recipes for success? Vaccine 2012, 30, 7344-7347. [CrossRef] [PubMed]
68. Cox, M.M.; Patriarca, P.A.; Treanor, J. Flublok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respir. Viruses 2008, 2, 211-219. [CrossRef] [PubMed]
69. Baker, S.F.; Guo, H.; Albrecht, R.A.; Garcia-Sastre, A.; Topham, D.J.; Martinez-Sobrido, L. Protection against lethal influenza with a viral mimic. J. Virol. 2013, 87, 8591-8605. [CrossRef] [PubMed]
70. Sun,W. Approval Letter-Fluarix Quadrivalent (BL 125127/513); U.S. Food and Drug Administration (FDA): Silver Spring, MD, USA, 2012.
71. Belongia, E.A.; Kieke, B.A.; Donahue, J.G.; Greenlee, R.T.; Balish, A.; Foust, A.; Lindstrom, S.; Shay, D.K. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J. Infect. Dis. 2009, 199, 159-167. [CrossRef] [PubMed]
72. Pica, N.; Palese, P. Toward a universal influenza virus vaccine: Prospects and challenges. Annu. Rev. Med. 2013, 64, 189-202. [CrossRef] [PubMed]
73. Gorse, G.J.; Belshe, R.B.; Munn, N.J. Superiority of live-attenuated compared with inactivated influenza A virus vaccines in older, chronically ill adults. Chest 1991, 100, 977-984. [CrossRef] [PubMed]
74. Garcia-Sastre, A. Antiviral response in pandemic influenza viruses. Emerg. Infect. Dis. 2006, 12, 44-47. [CrossRef] [PubMed]
75. Oxford, J.S.; Bossuyt, S.; Balasingam, S.; Mann, A.; Novelli, P.; Lambkin, R. Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors. Clin. Microbiol. Infect. 2003, 9, 1-14. [CrossRef] [PubMed]
76. Seibert, C.W.; Kaminski, M.; Philipp, J.; Rubbenstroth, D.; Albrecht, R.A.; Schwalm, F.; Stertz, S.; Medina, R.A.; Kochs, G.; Garcia-Sastre, A.; et al. Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J. Virol. 2010, 84, 11219-11226. [CrossRef] [PubMed]
77. Jackson, R.J.; Cooper, K.L.; Tappenden, P.; Rees, A.; Simpson, E.L.; Read, R.C.; Nicholson, K.G. Oseltamivir, zanamivir and amantadine in the prevention of influenza: A systematic review. J. Infect. 2011, 62, 14-25. [CrossRef] [PubMed]
78. Nguyen, J.T.; Hoopes, J.D.; Le, M.H.; Smee, D.F.; Patick, A.K.; Faix, D.J.; Blair, P.J.; de Jong, M.D.; Prichard, M.N.; Went, G.T. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS ONE 2010, 5, e9332. [CrossRef] [PubMed]
79. Hay, A.J.; Wolstenholme, A.J.; Skehel, J.J.; Smith, M.H. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 1985, 4, 3021-3024. [PubMed]
80. Gubareva, L.V.; Kaiser, L.; Hayden, F.G. Influenza virus neuraminidase inhibitors. Lancet 2000, 355, 827-835. [CrossRef]
81. Burnham, A.J.; Baranovich, T.; Govorkova, E.A. Neuraminidase inhibitors for influenza B virus infection: Efficacy and resistance. Antivir. Res. 2013, 100, 520-534. [CrossRef] [PubMed]
82. Farrukee, R.; Mosse, J.; Hurt, A.C. Review of the clinical effectiveness of the neuraminidase inhibitors against influenza B viruses. Expert Rev. Anti Infect. Ther. 2013, 11, 1135-1145. [CrossRef] [PubMed]
83. Pizzorno, A.; Abed, Y.; Boivin, G. Influenza drug resistance. Semin. Respir. Crit. Care Med. 2011, 32, 409-422. [CrossRef] [PubMed]
84. Nguyen, H.T.; Sheu, T.G.; Mishin, V.P.; Klimov, A.I.; Gubareva, L.V. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob. Agents Chemother. 2010, 54, 3671-3677. [CrossRef] [PubMed]
85. Ampofo, W.K.; Al Busaidy, S.; Cox, N.J.; Giovanni, M.; Hay, A.; Huang, S.; Inglis, S.; Katz, J.; Mokhtari-Azad, T.; Peiris, M.; et al. Strengthening the influenza vaccine virus selection and development process. In Presented at the 2ndWHOInformal Consultation for Improving Influenza Vaccine Virus Selection, Geneva, Switzerland, 7-9 December 2011.
86. Russell, C.A.; Jones, T.C.; Barr, I.G.; Cox, N.J.; Garten, R.J.; Gregory, V.; Gust, I.D.; Hampson, A.W.; Hay, A.J.; Hurt, A.C.; et al. Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine 2008, 26, D31-D34. [CrossRef] [PubMed]
87. Liang, S.; Mozdzanowska, K.; Palladino, G.; Gerhard,W. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol. 1994, 152, 1653-1661. [PubMed]
88. Medina, R.A.; Manicassamy, B.; Stertz, S.; Seibert, C.W.; Hai, R.; Belshe, R.B.; Frey, S.E.; Basler, C.F.; Palese, P.; Garcia-Sastre, A. Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus. Nat. Commun. 2010, 1, 28. [CrossRef] [PubMed]
89. Krammer, F.; Palese, P.; Steel, J. Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Curr. Top. Microbiol. Immunol. 2015, 386, 301-321. [PubMed]
90. Milian, E.; Kamen, A.A. Current and emerging cell culture manufacturing technologies for influenza vaccines. BioMed Res. Int. 2015, 2015, 504831. [CrossRef] [PubMed]
91. Katz, J.M.;Webster, R.G. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J. Infect. Dis. 1989, 160, 191-198. [CrossRef] [PubMed]
92. Meyer, W.J.; Wood, J.M.; Major, D.; Robertson, J.S.; Webster, R.G.; Katz, J.M. Influence of host cell-mediated variation on the international surveillance of influenza A (H3N2) viruses. Virology 1993, 196, 130-137. [CrossRef] [PubMed]
93. Ampofo,W.K.; Azziz-Baumgartner, E.; Bashir, U.; Cox, N.J.; Fasce, R.; Giovanni, M.; Grohmann, G.; Huang, S.; Katz, J.; Mironenko, A.; et al. Strengthening the influenza vaccine virus selection and development process. Presented at the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection, Geneva, Switzerland, 1-3 April 2014.
94. Salk, J.; Salk, D. Control of influenza and poliomyelitis with killed virus vaccines. Science 1977, 195, 834-847. [CrossRef] [PubMed]
95. De Villiers, P.J.; Steele, A.D.; Hiemstra, L.A.; Rappaport, R.; Dunning, A.J.; Gruber,W.C.; Forrest, B.D. Efficacy and safety of a live-attenuated influenza vaccine in adults 60 years of age and older. Vaccine 2009, 28, 228-234. [CrossRef] [PubMed]
96. Tlaxca, J.L.; Ellis, S.; Remmele, R.L., Jr. Live attenuated and inactivated viral vaccine formulation and nasal delivery: Potential and challenges. Adv. Drug. Deliv. Rev. 2015, 93, 56-78. [CrossRef] [PubMed]
97. Laver, W.G.; Webster, R.G. Preparation and immunogenicity of an influenza virus hemagglutinin and neuraminidase subunit vaccine. Virology 1976, 69, 511-522. [CrossRef]
98. Wong, S.S.; Webby, R.J. Traditional and new influenza vaccines. Clin. Microbiol. Rev. 2013, 26, 476-492. [CrossRef] [PubMed]
99. Duxbury, A.E.; Hampson, A.W.; Sievers, J.G. Antibody response in humans to deoxycholate-treated influenza virus vaccine. J. Immunol. 1968, 101, 62-67. [PubMed]
100. Baxter, R.; Patriarca, P.A.; Ensor, K.; Izikson, R.; Goldenthal, K.L.; Cox, M.M. Evaluation of the safety, reactogenicity and immunogenicity of flublok(r) trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 2011, 29, 2272-2278. [CrossRef] [PubMed]
101. Miller, G.L. A study of conditions for the optimum production of PR8 influenza virus in chick embryos. J. Exp. Med. 1944, 79, 173-183. [CrossRef] [PubMed]
102. Maassab, H.F.; Bryant, M.L. The development of live-attenuated cold-adapted influenza virus vaccine for humans. Rev. Med. Virol. 1999, 9, 237-244. [CrossRef]
103. Snyder, M.H.; Betts, R.F.; DeBorde, D.; Tierney, E.L.; Clements, M.L.; Herrington, D.; Sears, S.D.; Dolin, R.; Maassab, H.F.; Murphy, B.R. Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J. Virol. 1988, 62, 488-495. [PubMed]
104. Cox, N.J.; Kitame, F.; Kendal, A.P.; Maassab, H.F.; Naeve, C. Identification of sequence changes in the cold-adapted, live-attenuated influenza vaccine strain, A/Ann Arbor/6/60 (H2N2). Virology 1988, 167, 554-567. [CrossRef]
105. Maassab, H.F. Plaque formation of influenza virus at 25 °C. Nature 1968, 219, 645-646. [CrossRef] [PubMed]
106. Couch, R.B.; Keitel, W.A.; Cate, T.R. Improvement of inactivated influenza virus vaccines. J. Infect. Dis. 1997, 176, S38-S44. [CrossRef] [PubMed]
107. Chen, Z.; Aspelund, A.; Kemble, G.; Jin, H. Molecular studies of temperature-sensitive replication of the cold-adapted B/Ann Arbor/1/66, the master donor virus for live-attenuated influenza flumist vaccines. Virology 2008, 380, 354-362. [CrossRef] [PubMed]
108. Hoffmann, E.; Mahmood, K.; Chen, Z.; Yang, C.F.; Spaete, J.; Greenberg, H.B.; Herlocher, M.L.; Jin, H.; Kemble, G. Multiple gene segments control the temperature sensitivity and attenuation phenotypes of ca B/Ann Arbor/1/66. J. Virol. 2005, 79, 11014-11021. [CrossRef] [PubMed]
109. DeBorde, D.C.; Donabedian, A.M.; Herlocher, M.L.; Naeve, C.W.; Maassab, H.F. Sequence comparison of wild-type and cold-adapted B/Ann Arbor/1/66 influenza virus genes. Virology 1988, 163, 429-443. [CrossRef]
110. Donabedian, A.M.; DeBorde, D.C.; Maassab, H.F. Genetics of cold-adapted B/Ann Arbor/1/66 influenza virus reassortants: The acidic polymerase (PA) protein gene confers temperature sensitivity and attenuated virulence. Microb. Pathog. 1987, 3, 97-108. [CrossRef]
111. Chan, W.; Zhou, H.; Kemble, G.; Jin, H. The cold adapted and temperature sensitive influenza A/Ann Arbor/6/60 virus, the master donor virus for live-attenuated influenza vaccines, has multiple defects in replication at the restrictive temperature. Virology 2008, 380, 304-311. [CrossRef] [PubMed]
112. Jin, H.; Zhou, H.; Lu, B.; Kemble, G. Imparting temperature sensitivity and attenuation in ferrets to A/Puerto Rico/8/34 influenza virus by transferring the genetic signature for temperature sensitivity from cold-adapted A/Ann Arbor/6/60. J. Virol. 2004, 78, 995-998. [CrossRef] [PubMed]
113. Jin, H.; Lu, B.; Zhou, H.; Ma, C.; Zhao, J.; Yang, C.F.; Kemble, G.; Greenberg, H. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (flumist) derived from cold-adapted A/Ann Arbor/6/60. Virology 2003, 306, 18-24. [CrossRef]
114. Maassab, H.F. Adaptation and growth characteristics of influenza virus at 25 °C. Nature 1967, 213, 612-614. [CrossRef] [PubMed]
115. Cox, A.; Baker, S.F.; Nogales, A.; Martinez-Sobrido, L.; Dewhurst, S. Development of a mouse-adapted live-attenuated influenza virus that permits in vivo analysis of enhancements to the safety of live-attenuated influenza virus vaccine. J. Virol. 2015, 89, 3421-3426. [CrossRef] [PubMed]
116. Greenhawt, M.J. Influenza vaccination in asthmatic patients. J. Allergy Clin. Immunol. 2014, 133, 1233-1234. [CrossRef] [PubMed]
117. Belshe, R.B.; Gruber, W.C. Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2001, 356, 1947-1951. [PubMed]
118. Ghendon, Y.Z.; Polezhaev, F.I.; Lisovskaya, K.V.; Medvedeva, T.E.; Alexandrova, G.I.; Klimov, A.I. Recombinant cold-adapted attenuated influenza A vaccines for use in children: Molecular genetic analysis of the cold-adapted donor and recombinants. Infect. Immun. 1984, 44, 730-733. [PubMed]
119. Ghendon, Y.Z. Molecular characteristics and biological properties (genetic markers) of candidate strains for preparation of live influenza virus vaccines. Bull. World Health Organ. 1984, 62, 493-499. [PubMed]
120. Isakova-Sivak, I.; Chen, L.M.; Matsuoka, Y.; Voeten, J.T.; Kiseleva, I.; Heldens, J.G.; den Bosch, H.; Klimov, A.; Rudenko, L.; Cox, N.J.; et al. Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live-attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2). Virology 2011, 412, 297-305. [CrossRef] [PubMed]
121. Kendal, A.P. Cold-adapted live-attenuated influenza vaccines developed in russia: Can they contribute to meeting the needs for influenza control in other countries? Eur. J. Epidemiol. 1997, 13, 591-609. [CrossRef] [PubMed]
122. Hussain, A.I.; Cordeiro, M.; Sevilla, E.; Liu, J. Comparison of egg and high yielding MDCK cell-derived live-attenuated influenza virus for commercial production of trivalent influenza vaccine: In vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells. Vaccine 2010, 28, 3848-3855. [CrossRef] [PubMed]
123. Chen, Z.; Wang, W.; Zhou, H.; Suguitan, A.L., Jr.; Shambaugh, C.; Kim, L.; Zhao, J.; Kemble, G.; Jin, H. Generation of live-attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J. Virol. 2010, 84, 44-51. [CrossRef] [PubMed]
124. Pearson, H.E. Distribution of influenza virus type a in infected eggs and the survival of virus under certain conditions of storage. J. Bacteriol. 1944, 48, 369-378. [PubMed]
125. Voyles, C. A flu vaccine shortage can be devastating for LTC residents. RN 2005, 68, 10. [PubMed]
126. Stulc, J.P. The politics of the flu vaccine shortage. J. Ky. Med. Assoc. 2004, 102, 563-564. [PubMed]
127. Genzel, Y.; Reichl, U. Continuous cell lines as a production system for influenza vaccines. Expert Rev. Vaccines 2009, 8, 1681-1692. [CrossRef] [PubMed]
128. Le Ru, A.; Jacob, D.; Transfiguracion, J.; Ansorge, S.; Henry, O.; Kamen, A.A. Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing. Vaccine 2010, 28, 3661-3671. [CrossRef] [PubMed]
129. Merten, O.W.; Manuguerra, J.C.; Hannoun, C.; van der Werf, S. Production of influenza virus in serum-free mammalian cell cultures. Dev. Biol. Stand. 1999, 98, 23-37. [PubMed]
130. Merten, O.W.; Hannoun, C.; Manuguerra, J.C.; Ventre, F.; Petres, S. Production of influenza virus in cell cultures for vaccine preparation. Adv. Exp. Med. Biol. 1996, 397, 141-151. [PubMed]
131. Del Giudice, G.; Rappuoli, R. Inactivated and adjuvanted influenza vaccines. Curr. Top. Microbiol. Immunol. 2015, 386, 151-180. [PubMed]
132. Wu, J.; Liu, S.Z.; Dong, S.S.; Dong, X.P.; Zhang,W.L.; Lu, M.; Li, C.G.; Zhou, J.C.; Fang, H.H.; Liu, Y.; et al. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: A phase I-II randomized trial. Vaccine 2010, 28, 6221-6227. [CrossRef] [PubMed]
133. Black, S. Safety and effectiveness of MF-59 adjuvanted influenza vaccines in children and adults. Vaccine 2015, 33, B3-B5. [CrossRef] [PubMed]
134. Chen, W.H.; Jackson, L.A.; Edwards, K.M.; Keitel, W.A.; Hill, H.; Noah, D.L.; Creech, C.B.; Patel, S.M.; Mangal, B.; Kotloff, K.L. Persistence of antibody to influenza A/H5N1 vaccine virus: Impact of AS03 adjuvant. Clin. Vaccine. Immunol. 2016, 23, 73-77. [CrossRef] [PubMed]
135. Stobart, C.C.; Moore, M.L. RNA virus reverse genetics and vaccine design. Viruses 2014, 6, 2531-2550. [CrossRef] [PubMed]
136. Almazan, F.; Marquez-Jurado, S.; Nogales, A.; Enjuanes, L. Engineering infectious cDNAs of coronavirus as bacterial artificial chromosomes. Methods Mol. Biol. 2015, 1282, 135-152. [PubMed]
137. Almazan, F.; Dediego, M.L.; Galan, C.; Escors, D.; Alvarez, E.; Ortego, J.; Sola, I.; Zuniga, S.; Alonso, S.; Moreno, J.L.; et al. Construction of a severe acute respiratory syndrome coronavirus infectious cDNA clone and a replicon to study coronavirus RNA synthesis. J. Virol. 2006, 80, 10900-10906. [CrossRef] [PubMed]
138. Racaniello, V.R.; Baltimore, D. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science 1981, 214, 916-919. [CrossRef] [PubMed]
139. Martinez-Sobrido, L.; Garcia-Sastre, A. Generation of recombinant influenza virus from plasmid DNA. J. Vis. Exp. 2010, 42, e2057. [CrossRef] [PubMed]
140. Engelhardt, O.G. Many ways to make an influenza virus-Review of influenza virus reverse genetics methods. Influenza Other Respir. Viruses 2013, 7, 249-256. [CrossRef] [PubMed]
141. Nogales, A.; Baker, S.F.; Ortiz-Riano, E.; Dewhurst, S.; Topham, D.J.; Martinez-Sobrido, L. Influenza a virus attenuation by codon deoptimization of the NS gene for vaccine development. J. Virol. 2014, 88, 10525-10540. [CrossRef] [PubMed]
142. Nogales, A.; Baker, S.F.; Martinez-Sobrido, L. Replication-competent influenza A viruses expressing a red fluorescent protein. Virology 2014, 476C, 206-216. [CrossRef] [PubMed]
143. Martinez-Sobrido, L.; Cadagan, R.; Steel, J.; Basler, C.F.; Palese, P.; Moran, T.M.; Garcia-Sastre, A. Hemagglutinin-pseudotyped green fluorescent protein-expressing influenza viruses for the detection of influenza virus neutralizing antibodies. J. Virol. 2010, 84, 2157-2163. [CrossRef] [PubMed]
144. Nogales, A.; Baker, S.F.; Domm, W.; Martinez-Sobrido, L. Development and applications of single-cycle infectious influenza A virus (sciIAV). Virus Res. 2015, 216, 26-40. [CrossRef] [PubMed]
145. Breen, M.; Nogales, A.; Baker, S.F.; Martinez-Sobrido, L. Replication-competent influenza A viruses expressing reporter genes. Viruses 2016, 8, 179. [CrossRef] [PubMed]
146. Nogales, A.; Rodriguez-Sanchez, I.; Monte, K.; Lenschow, D.J.; Perez, D.R.; Martinez-Sobrido, L. Replication-competent fluorescent-expressing influenza B virus. Virus Res. 2015, 213, 69-81. [CrossRef] [PubMed]
147. Breen, M.; Nogales, A.; Baker, S.F.; Perez, D.R.; Martinez-Sobrido, L. Replication-competent influenza A and B viruses expressing a fluorescent dynamic timer protein for in vitro and in vivo studies. PLoS ONE 2016, 11, e0147723. [CrossRef] [PubMed]
148. Zobel, A.; Neumann, G.; Hobom, G. RNA polymerase I catalysed transcription of insert viral cDNA. Nucleic Acids Res. 1993, 21, 3607-3614. [CrossRef] [PubMed]
149. Neumann, G.; Zobel, A.; Hobom, G. RNA polymerase I-mediated expression of influenza viral RNA molecules. Virology 1994, 202, 477-479. [CrossRef] [PubMed]
150. Hoffmann, E.; Neumann, G.; Kawaoka, Y.; Hobom, G.; Webster, R.G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. USA 2000, 97, 6108-6113. [CrossRef] [PubMed]
151. Hoffmann, E.; Neumann, G.; Hobom, G.; Webster, R.G.; Kawaoka, Y. "Ambisense" approach for the generation of influenza A virus: vRNA and mRNA synthesis from one template. Virology 2000, 267, 310-317. [CrossRef] [PubMed]
152. Cheng, B.Y.; Ortiz-Riano, E.; de la Torre, J.C.; Martinez-Sobrido, L. Generation of recombinant arenavirus for vaccine development in fda-approved vero cells. J. Vis. Exp. 2013, 78, e50662. [CrossRef] [PubMed]
153. Ortiz-Riano, E.; Cheng, B.Y.; Carlos de la Torre, J.; Martinez-Sobrido, L. Arenavirus reverse genetics for vaccine development. J. Gen. Virol. 2013, 94, 1175-1188. [CrossRef] [PubMed]
154. Neumann, G.; Watanabe, T.; Ito, H.; Watanabe, S.; Goto, H.; Gao, P.; Hughes, M.; Perez, D.R.; Donis, R.; Hoffmann, E.; et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. USA 1999, 96, 9345-9350. [CrossRef] [PubMed]
155. Wang, Z.; Duke, G.M. Cloning of the canine RNA polymerase I promoter and establishment of reverse genetics for influenza A and B in MDCK cells. Virol. J. 2007, 4, 102. [CrossRef] [PubMed]
156. Massin, P.; Rodrigues, P.; Marasescu, M.; van der Werf, S.; Naffakh, N. Cloning of the chicken RNA polymerase I promoter and use for reverse genetics of influenza A viruses in avian cells. J. Virol. 2005, 79, 13811-13816. [CrossRef] [PubMed]
157. Zhang, X.; Curtiss, R., 3rd. Efficient generation of influenza virus with a mouse RNA polymerase I-driven all-in-one plasmid. Virol. J. 2015, 12, 95. [CrossRef] [PubMed]
158. Lu, G.; He, D.; Wang, Z.; Ou, S.; Yuan, R.; Li, S. Cloning the horse RNA polymerase I promoter and its application to studying influenza virus polymerase activity. Viruses 2016, 8, 119. [CrossRef] [PubMed]
159. Fodor, E.; Devenish, L.; Engelhardt, O.G.; Palese, P.; Brownlee, G.G.; Garcia-Sastre, A. Rescue of influenza A virus from recombinant DNA. J. Virol. 1999, 73, 9679-9682. [PubMed]
160. Zhou, B.; Lin, X.; Wang, W.; Halpin, R.A.; Bera, J.; Stockwell, T.B.; Barr, I.G.; Wentworth, D.E. Universal influenza B virus genomic amplification facilitates sequencing, diagnostics, and reverse genetics. J. Clin. Microbiol. 2014, 52, 1330-1337. [CrossRef] [PubMed]
161. Jackson, D.; Cadman, A.; Zurcher, T.; Barclay, W.S. A reverse genetics approach for recovery of recombinant influenza B viruses entirely from cDNA. J. Virol. 2002, 76, 11744-11747. [CrossRef] [PubMed]
162. Hoffmann, E.; Mahmood, K.; Yang, C.F.;Webster, R.G.; Greenberg, H.B.; Kemble, G. Rescue of influenza B virus from eight plasmids. Proc. Natl. Acad. Sci. USA 2002, 99, 11411-11416. [CrossRef] [PubMed]
163. Ozawa, M.; Kawaoka, Y. Taming influenza viruses. Virus Res. 2011, 162, 8-11. [CrossRef] [PubMed]
164. Marsh, G.A.; Hatami, R.; Palese, P. Specific residues of the influenza A virus hemagglutinin viral RNA are important for efficient packaging into budding virions. J. Virol. 2007, 81, 9727-9736. [CrossRef] [PubMed]
165. Isel, C.; Munier, S.; Naffakh, N. Experimental approaches to study genome packaging of influenza A viruses. Viruses 2016, 8, 218. [CrossRef] [PubMed]
166. Schickli, J.H.; Flandorfer, A.; Nakaya, T.; Martinez-Sobrido, L.; Garcia-Sastre, A.; Palese, P. Plasmid-only rescue of influenza A virus vaccine candidates. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2001, 356, 1965-1973. [PubMed]
167. Steel, J.; Lowen, A.C.; Pena, L.; Angel, M.; Solorzano, A.; Albrecht, R.; Perez, D.R.; Garcia-Sastre, A.; Palese, P. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J. Virol. 2009, 83, 1742-1753. [CrossRef] [PubMed]
168. Richt, J.A.; Garcia-Sastre, A. Attenuated influenza virus vaccines with modified NS1 proteins. Curr. Top. Microbiol. Immunol. 2009, 333, 177-195. [PubMed]
169. Vincent, A.L.; Ma,W.; Lager, K.M.; Janke, B.H.;Webby, R.J.; Garcia-Sastre, A.; Richt, J.A. Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine 2007, 25, 7999-8009. [CrossRef] [PubMed]
170. Quinlivan, M.; Zamarin, D.; Garcia-Sastre, A.; Cullinane, A.; Chambers, T.; Palese, P. Attenuation of equine influenza viruses through truncations of the NS1 protein. J. Virol. 2005, 79, 8431-8439. [CrossRef] [PubMed]
171. Falcon, A.M.; Fernandez-Sesma, A.; Nakaya, Y.; Moran, T.M.; Ortin, J.; Garcia-Sastre, A. Attenuation and immunogenicity in mice of temperature-sensitive influenza viruses expressing truncated NS1 proteins. J. Gen. Virol. 2005, 86, 2817-2821. [CrossRef] [PubMed]
172. Ferko, B.; Stasakova, J.; Romanova, J.; Kittel, C.; Sereinig, S.; Katinger, H.; Egorov, A. Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J. Virol. 2004, 78, 13037-13045. [CrossRef] [PubMed]
173. Richt, J.A.; Lekcharoensuk, P.; Lager, K.M.; Vincent, A.L.; Loiacono, C.M.; Janke, B.H.; Wu, W.H.; Yoon, K.J.; Webby, R.J.; Solorzano, A.; et al. Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine. J. Virol. 2006, 80, 11009-11018. [CrossRef] [PubMed]
174. Solorzano, A.; Webby, R.J.; Lager, K.M.; Janke, B.H.; Garcia-Sastre, A.; Richt, J.A. Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J. Virol. 2005, 79, 7535-7543. [CrossRef] [PubMed]
175. Wang, L.; Suarez, D.L.; Pantin-Jackwood, M.; Mibayashi, M.; Garcia-Sastre, A.; Saif, Y.M.; Lee, C.W. Characterization of influenza virus variants with different sizes of the non-structural (NS) genes and their potential as a live influenza vaccine in poultry. Vaccine 2008, 26, 3580-3586. [CrossRef] [PubMed]
176. Choi, E.H.; Song, M.S.; Park, S.J.; Pascua, P.N.; Baek, Y.H.; Kwon, H.I.; Kim, E.H.; Kim, S.; Jang, H.K.; Poo, H.; et al. Development of a dual-protective live-attenuated vaccine against H5N1 and H9N2 avian influenza viruses by modifying the NS1 gene. Arch. Virol. 2015, 160, 1729-1740. [CrossRef] [PubMed]
177. Nogales, A.; Huang, K.; Chauche, C.; DeDiego, M.L.; Murcia, P.R.; Parrish, C.R.; Martinez-Sobrido, L. Canine influenza viruses with modified NS1 proteins for the development of live-attenuated vaccines. Virology 2016, 500, 1-10. [CrossRef] [PubMed]
178. Baskin, C.R.; Bielefeldt-Ohmann, H.; Garcia-Sastre, A.; Tumpey, T.M.; van Hoeven, N.; Carter, V.S.; Thomas, M.J.; Proll, S.; Solorzano, A.; Billharz, R.; et al. Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus. J. Virol. 2007, 81, 11817-11827. [CrossRef] [PubMed]
179. Pica, N.; Langlois, R.A.; Krammer, F.; Margine, I.; Palese, P. NS1-truncated live-attenuated virus vaccine provides robust protection to aged mice from viral challenge. J. Virol. 2012, 86, 10293-10301. [CrossRef] [PubMed]
180. Hai, R.;Martinez-Sobrido, L.; Fraser, K.A.; Ayllon, J.; Garcia-Sastre, A.; Palese, P. Influenza B virusNS1-truncated mutants: Live-attenuated vaccine approach. J. Virol. 2008, 82, 10580-10590. [CrossRef] [PubMed]
181. Talon, J.; Salvatore, M.; O’Neill, R.E.; Nakaya, Y.; Zheng, H.; Muster, T.; Garcia-Sastre, A.; Palese, P. Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc. Natl. Acad. Sci. USA 2000, 97, 4309-4314. [CrossRef] [PubMed]
182. Cheng, B.Y.; Ortiz-Riano, E.; Nogales, A.; de la Torre, J.C.;Martinez-Sobrido, L. Development of live-attenuated arenavirus vaccines based on codon deoptimization. J. Virol. 2015, 89, 3523-3533. [CrossRef] [PubMed]
183. Mueller, S.; Coleman, J.R.; Papamichail, D.; Ward, C.B.; Nimnual, A.; Futcher, B.; Skiena, S.; Wimmer, E. Live attenuated influenza virus vaccines by computer-aided rational design. Nat. Biotechnol. 2010, 28, 723-726. [CrossRef] [PubMed]
184. Yang, C.; Skiena, S.; Futcher, B.; Mueller, S.; Wimmer, E. Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraprotective live vaccine in mice. Proc. Natl. Acad. Sci. USA 2013, 110, 9481-9486. [CrossRef] [PubMed]
185. Katsura, H.; Iwatsuki-Horimoto, K.; Fukuyama, S.; Watanabe, S.; Sakabe, S.; Hatta, Y.; Murakami, S.; Shimojima, M.; Horimoto, T.; Kawaoka, Y. A replication-incompetent virus possessing an uncleavable hemagglutinin as an influenza vaccine. Vaccine 2012, 30, 6027-6033. [CrossRef] [PubMed]
186. Powell, T.J.; Silk, J.D.; Sharps, J.; Fodor, E.; Townsend, A.R. Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity. J. Virol. 2012, 86, 13397-13406. [CrossRef] [PubMed]
187. Shinya, K.; Fujii, Y.; Ito, H.; Ito, T.; Kawaoka, Y. Characterization of a neuraminidase-deficient influenza A virus as a potential gene delivery vector and a live vaccine. J. Virol. 2004, 78, 3083-3088. [CrossRef] [PubMed]
188. Uraki, R.; Kiso, M.; Iwatsuki-Horimoto, K.; Fukuyama, S.; Takashita, E.; Ozawa, M.; Kawaoka, Y. A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges. J. Virol. 2013, 87, 7874-7881. [CrossRef] [PubMed]
189. Victor, S.T.; Watanabe, S.; Katsura, H.; Ozawa, M.; Kawaoka, Y. A replication-incompetent PB2-knockout influenza A virus vaccine vector. J. Virol. 2012, 86, 4123-4128. [CrossRef] [PubMed]
190. Guo, H.; Baker, S.F.; Martinez-Sobrido, L.; Topham, D.J. Induction of CD8 T cell heterologous protection by a single dose of single-cycle infectious influenza virus. J. Virol. 2014, 88, 12006-12016. [CrossRef] [PubMed]
191. Masic, A.; Pyo, H.M.; Babiuk, S.; Zhou, Y. An eight-segment swine influenza virus harboring H1 and H3 hemagglutinins is attenuated and protective against H1N1 and H3N2 subtypes in pigs. J. Virol. 2013, 87, 10114-10125. [CrossRef] [PubMed]
192. Fonseca, W.; Ozawa, M.; Hatta, M.; Orozco, E.; Martinez, M.B.; Kawaoka, Y. A recombinant influenza virus vaccine expressing the f protein of respiratory syncytial virus. Arch. Virol. 2014, 159, 1067-1077. [CrossRef] [PubMed]
193. Kobayashi, H.; Iwatsuki-Horimoto, K.; Kiso, M.; Uraki, R.; Ichiko, Y.; Takimoto, T.; Kawaoka, Y. A replication-incompetent influenza virus bearing the hn glycoprotein of human parainfluenza virus as a bivalent vaccine. Vaccine 2013, 31, 6239-6246. [CrossRef] [PubMed]
194. Katsura, H.; Piao, Z.; Iwatsuki-Horimoto, K.; Akeda, Y.;Watanabe, S.; Horimoto, T.; Oishi, K.; Kawaoka, Y. A bivalent vaccine based on a replication-incompetent influenza virus protects against streptococcus pneumoniae and influenza virus infection. J. Virol. 2014, 88, 13410-13417. [CrossRef] [PubMed]
195. Pena, L.; Sutton, T.; Chockalingam, A.; Kumar, S.; Angel, M.; Shao, H.; Chen, H.; Li,W.; Perez, D.R. Influenza viruses with rearranged genomes as live-attenuated vaccines. J. Virol. 2013, 87, 5118-5127. [CrossRef] [PubMed]
196. Nogales, A.; DeDiego, M.L.; Topham, D.J.; Martinez-Sobrido, L. Rearrangement of influenza virus spliced segments for the development of live-attenuated vaccines. J. Virol. 2016. [CrossRef] [PubMed]
197. Perez, D.R.; Garcia-Sastre, A. H5N1, a wealth of knowledge to improve pandemic preparedness. Virus Res. 2013, 178, 1-2. [CrossRef] [PubMed]
198. Perez, D.R.; Lim, W.; Seiler, J.P.; Yi, G.; Peiris, M.; Shortridge, K.F.; Webster, R.G. Role of quail in the interspecies transmission of H9 influenza A viruses: Molecular changes on HA that correspond to adaptation from ducks to chickens. J. Virol. 2003, 77, 3148-3156. [CrossRef] [PubMed]
199. Deng, L.; Cho, K.J.; Fiers,W.; Saelens, X. M2e-based universal influenza A vaccines. Vaccines 2015, 3, 105-136. [CrossRef] [PubMed]
200. Wilson, I.A.; Skehel, J.J.;Wiley, D.C. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 1981, 289, 366-373. [CrossRef] [PubMed]
201. Zhang, H.; Wang, L.; Compans, R.W.; Wang, B.Z. Universal influenza vaccines, a dream to be realized soon. Viruses 2014, 6, 1974-1991. [CrossRef] [PubMed]
202. +T cells by dendritic cells pulsed with an influenza virus-like particle (VLP) vaccine. Vaccine 2010, 28, 5524-5532. [CrossRef] [PubMed]
203. Latham, T.; Galarza, J.M. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J. Virol. 2001, 75, 6154-6165. [CrossRef] [PubMed]
204. Pushko, P.; Tumpey, T.M.; Bu, F.; Knell, J.; Robinson, R.; Smith, G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005, 23, 5751-5759. [CrossRef] [PubMed]
205. Chen, B.J.; Leser, G.P.; Morita, E.; Lamb, R.A. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J. Virol. 2007, 81, 7111-7123. [CrossRef] [PubMed]
206. Pushko, P.; Pearce, M.B.; Ahmad, A.; Tretyakova, I.; Smith, G.; Belser, J.A.; Tumpey, T.M. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Vaccine 2011, 29, 5911-5918. [CrossRef] [PubMed]